logo
Discover Placerville CA luxury farmhouse designed for ultimate entertainment

Discover Placerville CA luxury farmhouse designed for ultimate entertainment

Yahoo12-04-2025
Inside Look is a Sacramento Bee series where we take readers behind the scenes at restaurants, new businesses, local landmarks and news stories.
Bill Roberts designed his Placerville home to be an entertainer's paradise.
Objective achieved.
Roberts, founder of Good Guys Heating and Cooling, and his wife Ashley purchased the five-acre property east of Sacramento in 2019 for $535,000, according to public property records. They significantly renovated and expanded the existing, smaller home and added substantial outdoor amenities and landscaping.
The original residence was built in the 1970s, but it's 'basically like new construction,' said listing agent Callie Mirsky of Cali Homes. She helped the couple purchase the property six years ago when 'it looked drastically different.'
The property at 4244 Boles Road recently hit the market for $2.2 million.
The architecture is a blend of ranch or country style and contemporary luxury design. High-end amenities throughout the residence add a modern, spacious and appealing aesthetic. The open-concept layout flows front to back.
A sweeping backyard deck and outdoor kitchen offering stunning views of the snow-capped peaks of the Sierra Nevada is the icing on the cake.
Spectacular gathering spaces are found at every turn, starting at the front entry and running to the back of the property where a full, covered bar awaits. The charming venue-style cantina provides numerous tables, a large fire pit, two restrooms, speakers, space for dancing and heating.
The home spans 4,200 square feet with three bedrooms — including a primary suite and junior primary suite. The house 'lives like a single level,' Mirsky said, but up the stairs there's an incredible movie theater with an abundance of seats, as well as a concession area and a bathroom.
The expansive gourmet kitchen sits just above the large family room adjacent to a big dining area. The kitchen features an oversized island, dining bar and plenty of storage, including a butler's pantry.
The dining room opens out to a gorgeous rear veranda overlooking a park-like backyard, where meandering paths lead through large grassy areas and down to the rustic bar, fenced pastures and a sizeable chicken coop.
The outdoor kitchen on the deck is impressive. It features a pizza oven, flat-top and regular grills, surround sound, wine fridge, a heating and cooling system underneath and retractable shades. The space is large enough for a firepit and a Jacuzzi-style spa, too.
'I don't know what more you could want,' Mirsky said.
The property is a hobbyist's and recreation enthusiast's fantasy. A 2,500-square-foot detached shop with heating and air conditioning provides enough space for a car collector to store up to 12 vehicles. The workshop comes with a well-equipped insulated loft that provides a fun place to hang out. The hideaway has a half bathroom, television, refrigerators and pool table.
Additional covered RV and boat storage is accessed from the other side of the home.
'There's room for all the toys,' MIrsky said.
The primary bedroom, which overlooks the backyard, comes with a standalone luxurious bathtub, large walk-in closet with organizers and an oversized shower.
The house contains practically everything a homeowner would want inside, but the design allows for versatility. For example, a big utility room includes office space with a built-in desk, a fitted dog crate, a washer and dryer and a large island for folding clothes or doing crafts or work projects.
With the movie theater and bathroom up the stairs from the utility room, the wing could be transformed into separate living quarters for guests or family members. It has private access.
Roberts and his wife planned to add a pool or pond to the property — there's plenty of space — but hadn't gotten around to it yet, Mirsky said.
The couple are selling the Boles Road property after purchasing 160 acres nearby for their next endeavor, raising cattle, Mirsky said.
'Magical' estate offers 360-degree mountain, river and vineyard views east of Sacramento
See $8M NorCal home built to resist fires — and to dazzle with its modern design
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

August 2025's Promising Penny Stocks In Global Market
August 2025's Promising Penny Stocks In Global Market

Yahoo

time5 hours ago

  • Yahoo

August 2025's Promising Penny Stocks In Global Market

As global markets navigate a landscape marked by interest rate adjustments and shifting trade dynamics, investors are keenly observing the opportunities that arise amidst these changes. Penny stocks, often seen as relics of earlier market days, still hold relevance by offering exposure to smaller or newer companies with potential for growth. By identifying those with strong financials and promising outlooks, investors can find compelling opportunities in this segment of the market. Top 10 Penny Stocks Globally Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$2.39 A$109.91M ★★★★★★ Lever Style (SEHK:1346) HK$1.47 HK$915.41M ★★★★★★ GTN (ASX:GTN) A$0.405 A$74.36M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.49 HK$2.1B ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ MGB Berhad (KLSE:MGB) MYR0.505 MYR298.78M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.88 SGD11.33B ★★★★★☆ Zetrix AI Berhad (KLSE:ZETRIX) MYR0.90 MYR6.92B ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.155 £183.58M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.934 €31.5M ★★★★★★ Click here to see the full list of 3,784 stocks from our Global Penny Stocks screener. Let's uncover some gems from our specialized screener. Goldpac Group Simply Wall St Financial Health Rating: ★★★★★★ Overview: Goldpac Group Limited is an investment holding company that offers embedded software, secure payment products, and smart financial self-service kiosks in Mainland China and internationally, with a market cap of HK$918.61 million. Operations: The company's revenue is derived from two main segments: Platform and Service, generating CN¥472.94 million, and Embedded Software and Secure Payment Products, contributing CN¥622.36 million. Market Cap: HK$918.61M Goldpac Group Limited, with a market cap of HK$918.61 million, is experiencing challenges as its revenue and profit are expected to decline by 10%-20% and 20%-30% respectively for the first half of 2025 compared to the previous year. Despite being debt-free and having high-quality earnings, the company's return on equity is low at 2.5%, and its profit margins have decreased from last year's figures. The management team is experienced with an average tenure of nine years, but recent board changes may impact strategic direction. The stock trades significantly below estimated fair value but faces unstable dividend records. Dive into the specifics of Goldpac Group here with our thorough balance sheet health report. Assess Goldpac Group's previous results with our detailed historical performance reports. ValueMax Group Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: ValueMax Group Limited, with a market cap of SGD729.63 million, operates in Singapore focusing on pawnbroking, moneylending, jewelry and watches retailing, and gold trading businesses. Operations: There are no specific revenue segments reported for the company. Market Cap: SGD729.63M ValueMax Group Limited, with a market cap of SGD729.63 million, reported strong half-year earnings growth, with sales reaching SGD 268.34 million and net income at SGD 48.03 million, both up from the previous year. Despite high-quality earnings and improved profit margins (19.3%), the company's operating cash flow remains negative, impacting debt coverage and dividend sustainability (3.44%). While its short-term assets significantly exceed liabilities, indicating solid liquidity management, ValueMax's net debt to equity ratio is high at 126.2%. The stock trades below fair value estimates but benefits from experienced management and board teams. Take a closer look at ValueMax Group's potential here in our financial health report. Learn about ValueMax Group's historical performance here. Huapont Life SciencesLtd Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Huapont Life Sciences Co., Ltd. operates in the fields of medicine, medical care, agrochemicals, new materials, and tourism both in China and internationally with a market cap of CN¥8.74 billion. Operations: Huapont Life Sciences Co., Ltd. has not reported specific revenue segments, but it operates across various sectors including medicine, medical care, agrochemicals, new materials, and tourism both domestically and internationally. Market Cap: CN¥8.74B Huapont Life Sciences Co., Ltd., with a market cap of CN¥8.74 billion, operates across diverse sectors but remains unprofitable, facing challenges in earnings growth and profitability. The management team is experienced, with an average tenure of 11.6 years, and the board also brings seasoned expertise. Despite its financial struggles, the company has managed to reduce its debt to equity ratio from 82.6% to 59.7% over five years and maintains satisfactory net debt levels at 31.6%. Recent changes include amendments to company bylaws and the election of Zhang Songshan as a non-independent director. Get an in-depth perspective on Huapont Life SciencesLtd's performance by reading our balance sheet health report here. Understand Huapont Life SciencesLtd's track record by examining our performance history report. Seize The Opportunity Gain an insight into the universe of 3,784 Global Penny Stocks by clicking here. Searching for a Fresh Perspective? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:3315 SGX:T6I and SZSE:002004. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Asian Market Highlights: Penny Stocks To Watch In August 2025
Asian Market Highlights: Penny Stocks To Watch In August 2025

Yahoo

time10 hours ago

  • Yahoo

Asian Market Highlights: Penny Stocks To Watch In August 2025

As global markets navigate a landscape marked by shifting trade policies and monetary adjustments, the Asian market continues to capture attention with its diverse economic activities and robust stock performances. Amidst this backdrop, penny stocks—though an older term—remain a focal point for investors seeking potential growth in smaller or newer companies. By identifying those with strong financial health, investors can uncover opportunities that balance risk with promising returns. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.30 THB4.25B ★★★★★☆ JBM (Healthcare) (SEHK:2161) HK$2.86 HK$2.33B ★★★★★★ Lever Style (SEHK:1346) HK$1.48 HK$915.41M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.52 HK$2.1B ★★★★★★ China Sunsine Chemical Holdings (SGX:QES) SGD0.68 SGD648.3M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.88 SGD11.33B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.95 THB1.4B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Rojana Industrial Park (SET:ROJNA) THB4.82 THB9.74B ★★★★★★ BRC Asia (SGX:BEC) SGD3.55 SGD973.94M ★★★★★★ Click here to see the full list of 977 stocks from our Asian Penny Stocks screener. Let's review some notable picks from our screened stocks. K. Wah International Holdings Simply Wall St Financial Health Rating: ★★★★★★ Overview: K. Wah International Holdings Limited is an investment holding company involved in property development and investment in Hong Kong and Mainland China, with a market capitalization of approximately HK$7.79 billion. Operations: The company's revenue is primarily derived from property development in Mainland China (HK$5.91 billion) and Hong Kong (HK$540.49 million), along with property investment generating HK$642.97 million. Market Cap: HK$7.79B K. Wah International Holdings, with a market capitalization of HK$7.79 billion, derives substantial revenue from property development in Mainland China and Hong Kong. It has managed to reduce its debt-to-equity ratio over the past five years, maintaining a satisfactory net debt level relative to equity. The company's short-term assets significantly exceed both its short- and long-term liabilities, reflecting strong liquidity. However, recent earnings have declined sharply by 58.2%, with forecasts indicating further declines over the next three years. Despite trading below estimated fair value, its return on equity remains low at 0.9%, and dividend stability is uncertain due to an unstable track record. Click here and access our complete financial health analysis report to understand the dynamics of K. Wah International Holdings. Learn about K. Wah International Holdings' future growth trajectory here. China Shanshui Cement Group Simply Wall St Financial Health Rating: ★★★★★☆ Overview: China Shanshui Cement Group Limited is an investment holding company that manufactures and sells cement, clinker, concrete, and related products and services in the People's Republic of China, with a market cap of HK$3.83 billion. Operations: The company generates CN¥13.50 billion in revenue from its operations in manufacturing and trading cement, clinker, and concrete. Market Cap: HK$3.83B China Shanshui Cement Group has seen a volatile share price recently, reflecting broader challenges in the sector. Despite becoming profitable last year, its earnings have been impacted by large one-off items and declining sales, with recent half-year revenue at CN¥5.55 billion compared to CN¥6.57 billion previously. The company reported a net loss of CN¥250 million for the same period but has improved from a larger loss last year. Its debt management is prudent with a satisfactory net debt to equity ratio of 13.2%, though short-term liabilities exceed assets, posing potential liquidity concerns amidst ongoing legal issues and governance changes. Click here to discover the nuances of China Shanshui Cement Group with our detailed analytical financial health report. Explore historical data to track China Shanshui Cement Group's performance over time in our past results report. Fuan Pharmaceutical (Group) Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Fuan Pharmaceutical (Group) Co., Ltd. is engaged in the research, development, production, and sale of chemical drugs in China with a market cap of CN¥5.85 billion. Operations: The company generates CN¥2.05 billion in revenue from its pharmaceutical industry segment. Market Cap: CN¥5.85B Fuan Pharmaceutical (Group) Co., Ltd. offers a stable investment profile within the penny stock segment, with its CN¥2.05 billion revenue from pharmaceuticals and a market cap of CN¥5.85 billion. The company boasts seasoned management and board teams, with average tenures of 14.3 and 3.7 years respectively, supporting strategic continuity. Short-term assets comfortably cover both short- and long-term liabilities, while operating cash flow adequately covers debt obligations at 20%. Despite negative earnings growth last year, profit margins improved to 11% from 9.7%, indicating operational resilience amid challenges in the broader pharmaceutical industry landscape. Navigate through the intricacies of Fuan Pharmaceutical (Group) with our comprehensive balance sheet health report here. Gain insights into Fuan Pharmaceutical (Group)'s past trends and performance with our report on the company's historical track record. Seize The Opportunity Click through to start exploring the rest of the 974 Asian Penny Stocks now. Interested In Other Possibilities? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:173 SEHK:691 and SZSE:300194. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Asian Market Highlights: Penny Stocks To Watch In August 2025
Asian Market Highlights: Penny Stocks To Watch In August 2025

Yahoo

time10 hours ago

  • Yahoo

Asian Market Highlights: Penny Stocks To Watch In August 2025

As global markets navigate a landscape marked by shifting trade policies and monetary adjustments, the Asian market continues to capture attention with its diverse economic activities and robust stock performances. Amidst this backdrop, penny stocks—though an older term—remain a focal point for investors seeking potential growth in smaller or newer companies. By identifying those with strong financial health, investors can uncover opportunities that balance risk with promising returns. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.30 THB4.25B ★★★★★☆ JBM (Healthcare) (SEHK:2161) HK$2.86 HK$2.33B ★★★★★★ Lever Style (SEHK:1346) HK$1.48 HK$915.41M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.52 HK$2.1B ★★★★★★ China Sunsine Chemical Holdings (SGX:QES) SGD0.68 SGD648.3M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.88 SGD11.33B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.95 THB1.4B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Rojana Industrial Park (SET:ROJNA) THB4.82 THB9.74B ★★★★★★ BRC Asia (SGX:BEC) SGD3.55 SGD973.94M ★★★★★★ Click here to see the full list of 977 stocks from our Asian Penny Stocks screener. Let's review some notable picks from our screened stocks. K. Wah International Holdings Simply Wall St Financial Health Rating: ★★★★★★ Overview: K. Wah International Holdings Limited is an investment holding company involved in property development and investment in Hong Kong and Mainland China, with a market capitalization of approximately HK$7.79 billion. Operations: The company's revenue is primarily derived from property development in Mainland China (HK$5.91 billion) and Hong Kong (HK$540.49 million), along with property investment generating HK$642.97 million. Market Cap: HK$7.79B K. Wah International Holdings, with a market capitalization of HK$7.79 billion, derives substantial revenue from property development in Mainland China and Hong Kong. It has managed to reduce its debt-to-equity ratio over the past five years, maintaining a satisfactory net debt level relative to equity. The company's short-term assets significantly exceed both its short- and long-term liabilities, reflecting strong liquidity. However, recent earnings have declined sharply by 58.2%, with forecasts indicating further declines over the next three years. Despite trading below estimated fair value, its return on equity remains low at 0.9%, and dividend stability is uncertain due to an unstable track record. Click here and access our complete financial health analysis report to understand the dynamics of K. Wah International Holdings. Learn about K. Wah International Holdings' future growth trajectory here. China Shanshui Cement Group Simply Wall St Financial Health Rating: ★★★★★☆ Overview: China Shanshui Cement Group Limited is an investment holding company that manufactures and sells cement, clinker, concrete, and related products and services in the People's Republic of China, with a market cap of HK$3.83 billion. Operations: The company generates CN¥13.50 billion in revenue from its operations in manufacturing and trading cement, clinker, and concrete. Market Cap: HK$3.83B China Shanshui Cement Group has seen a volatile share price recently, reflecting broader challenges in the sector. Despite becoming profitable last year, its earnings have been impacted by large one-off items and declining sales, with recent half-year revenue at CN¥5.55 billion compared to CN¥6.57 billion previously. The company reported a net loss of CN¥250 million for the same period but has improved from a larger loss last year. Its debt management is prudent with a satisfactory net debt to equity ratio of 13.2%, though short-term liabilities exceed assets, posing potential liquidity concerns amidst ongoing legal issues and governance changes. Click here to discover the nuances of China Shanshui Cement Group with our detailed analytical financial health report. Explore historical data to track China Shanshui Cement Group's performance over time in our past results report. Fuan Pharmaceutical (Group) Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Fuan Pharmaceutical (Group) Co., Ltd. is engaged in the research, development, production, and sale of chemical drugs in China with a market cap of CN¥5.85 billion. Operations: The company generates CN¥2.05 billion in revenue from its pharmaceutical industry segment. Market Cap: CN¥5.85B Fuan Pharmaceutical (Group) Co., Ltd. offers a stable investment profile within the penny stock segment, with its CN¥2.05 billion revenue from pharmaceuticals and a market cap of CN¥5.85 billion. The company boasts seasoned management and board teams, with average tenures of 14.3 and 3.7 years respectively, supporting strategic continuity. Short-term assets comfortably cover both short- and long-term liabilities, while operating cash flow adequately covers debt obligations at 20%. Despite negative earnings growth last year, profit margins improved to 11% from 9.7%, indicating operational resilience amid challenges in the broader pharmaceutical industry landscape. Navigate through the intricacies of Fuan Pharmaceutical (Group) with our comprehensive balance sheet health report here. Gain insights into Fuan Pharmaceutical (Group)'s past trends and performance with our report on the company's historical track record. Seize The Opportunity Click through to start exploring the rest of the 974 Asian Penny Stocks now. Interested In Other Possibilities? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:173 SEHK:691 and SZSE:300194. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store